Lixte Biotechnology notifies CMO James Miser of non-renewal; employment ends July 31, 2024

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Dr. James Miser's employment agreement not renewed; CMO role ends July 31, 2024.
Lixte intends to appoint a new Chief Medical Officer effective August 1, 2024.
Notice of non-renewal provided to Dr. Miser on May 24, 2024.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

James Miser

Chief Medical Officer

LIXT · LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Effective: 2024-07-31
Filed: May 29, 2024, 7:59 PM ET

On May 24, 2024, Lixte Biotechnology Holdings, Inc. (the “Company”) provided notice to Dr. James Miser that it has elected not to renew the employment agreement between the Company and Dr. Miser pursuant to which Dr. Miser has served as the Company’s Chief Medical Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

James Miser departed as Chief Medical Officer at LIXTE BIOTECHNOLOGY HOLDINGS, INC..

Action: elected not to renew
Role: Chief Medical Officer

Exact text from the filing

On May 24, 2024, Lixte Biotechnology Holdings, Inc. (the “Company”) provided notice to Dr. James Miser that it has elected not to renew the employment agreement between the Company and Dr. Miser pursuant to which Dr. Miser has served as the Company’s Chief Medical Officer.

View on SEC.gov

LIXTE BIOTECHNOLOGY HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001493152-24-021837

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.